Inhibikase Therapeutics Announces a 1-for-6 Reverse Stock Split

BOSTON and ATLANTA, June 29, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of

Related Keywords

Massachusetts ,United States ,Atlanta ,Georgia ,Boston ,American ,Miltonh Werner ,Alex Lobo ,Youtube ,Inhibikase Or Company ,Twitter ,Nasdaq ,American Stock Transfer Trust Company ,Company Contact ,Facebook ,Sternir Inc ,Exchange Commission ,Prnewswire Inhibikase Therapeutics Inc ,Linkedin ,Inhibikase Therapeutics Inc ,Abelson Tyrosine Kinases ,Nasdaq Capital Market ,American Stock Transfer ,Trust Company ,Abelson Tyrosine Kinase ,Ableson Tyrosine ,Multiple System Atrophy ,Private Securities Litigation Reform Act ,